Search Results

You are looking at 31 - 40 of 449 items for :

  • Refine by Access: All x
Clear All
Full access

In 2006, an estimated 62,190 new cases of melanoma will be diagnosed, and approximately 7910 patients will die of the disease in the United States. The incidence of melanoma continues to increase dramatically. Risk factors for melanoma include family history, dysplastic nevi, and fair skin that sunburns easily; however, melanoma can occur in any ethnic group and in people who have not had substantial sun exposure. The NCCN Melanoma guidelines attempt to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms.

For the most recent version of the guidelines, please visit NCCN.org

Full access

John A. Thompson

“The NCCN Guidelines for melanoma have come a long way,” said John A. Thompson, MD, Co-Director of the Melanoma Clinic at the Seattle Cancer Care Alliance, member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center

Full access

John A. Thompson

John A. Thompson, MD, Co-Director, Melanoma Clinic, Seattle Cancer Care Alliance, Seattle, presented an update on melanoma and discussed new treatments at the 19th NCCN Annual Conference. “In the past, treatments for metastatic melanoma were

Full access

NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019

Featured Updates to the NCCN Guidelines

P. Kumar Rao, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, John A. Thompson, Mark R. Albertini, Genevieve Boland, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossman, Valerie Guild, Douglas Johnson, Giorgos Karakousis, Julie R. Lange, ScM, Kim Margolin, Sameer Nath, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Evan Wuthrick, Nicole R. McMillian, and Anita Engh

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Uveal Melanoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Uveal Melanoma Disclosure of Relevant Financial

Full access

Douglas B. Johnson and Jeffrey A. Sosman

/print certificate. Release date: May 9, 2014; Expiration date: May 9, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Evaluate immune-based therapies and BRAF inhibitors for patients with melanoma Outline

Full access

Sari M. Fien and Allan R. Oseroff

photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA) . Photochem Photobiol 1995 ; 61 : 523 – 528 . 8. Szeimies RM Karrer S . Towards a more specific therapy: targeting non-melanoma

Full access

Michelle T. Ashworth and Adil Daud

/print certificate. Release date: March 10, 2014; Expiration date: March 10, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the long-term management of patients with metastatic melanoma using targeted

Full access

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

Background : Both immunotherapy (IO) and targeted therapy, specifically dabrafenib + trametinib (DT), are recommended by the NCCN guidelines for the management of BRAF+ cutaneous melanoma in the adjuvant setting. However, data surrounding their

Full access

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

Featured Updates to the NCCN Guidelines

Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Melanoma: Cutaneous Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma: Cutaneous

Full access

Michael S. Sabel and Vernon K. Sondak

No benefits or funds were received in support of this study. References 1 Balch CM Buzaid AC Soong S-J . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma . J Clin Oncol 2001 ; 19